Neximmune Stock Buy Hold or Sell Recommendation
| NEXI Stock | USD 3.65 0.16 4.58% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Neximmune is 'Cautious Hold'. Macroaxis provides Neximmune buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding NEXI positions. The advice algorithm takes into account all of Neximmune's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Neximmune's buy or sell advice are summarized below:
Real Value 2.75 | Target Price 2 | Hype Value 3.58 | Market Value 3.65 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Neximmune given historical horizon and risk tolerance towards Neximmune. When Macroaxis issues a 'buy' or 'sell' recommendation for Neximmune, the advice is generated through an automated system that utilizes algorithms and statistical models.
Neximmune |
Execute Neximmune Buy or Sell Advice
The Neximmune recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Neximmune. Macroaxis does not own or have any residual interests in Neximmune or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Neximmune's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Weak | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Neximmune Trading Alerts and Improvement Suggestions
| Neximmune had very high historical volatility over the last 90 days | |
| Neximmune has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (32.34 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neximmune currently holds about 53.13 M in cash with (31.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.2. | |
| Neximmune has a frail financial position based on the latest SEC disclosures | |
| Roughly 21.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from investorplace.com: NEXI Stock Earnings NexImmune Reported Results for Q4 2023 |
Neximmune Returns Distribution Density
The distribution of Neximmune's historical returns is an attempt to chart the uncertainty of Neximmune's future price movements. The chart of the probability distribution of Neximmune daily returns describes the distribution of returns around its average expected value. We use Neximmune price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Neximmune returns is essential to provide solid investment advice for Neximmune.
| Mean Return | -0.62 | Value At Risk | -16.37 | Potential Upside | 12.44 | Standard Deviation | 13.89 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Neximmune historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Neximmune Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Neximmune is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Neximmune backward and forwards among themselves. Neximmune's institutional investor refers to the entity that pools money to purchase Neximmune's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jane Street Group, Llc | 2023-09-30 | 0.0 | Caprock Group Inc | 2023-12-31 | 0.0 | Envestnet Asset Management Inc | 2023-09-30 | 0.0 | Davenport & Company Llc | 2023-09-30 | 0.0 | Hrt Financial Llc | 2023-09-30 | 0.0 | Slate Path Capital Lp | 2023-12-31 | 37 K | Adage Capital Partners Gp Llc | 2023-12-31 | 32.1 K | Epiq Capital Group, Llc | 2023-12-31 | 15.6 K | Pnc Financial Services Group Inc | 2023-12-31 | 12.6 K | Comerica Bank | 2023-12-31 | 3.3 K | Tower Research Capital Llc | 2023-12-31 | 1.8 K |
Neximmune Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | 10.7M | 1.0M | (51.5M) | 50.3M | (187.7K) | (197.0K) | |
| Change In Cash | 8.8M | (4.1M) | 25.3M | 4.3M | (31.5M) | (29.9M) | |
| Free Cash Flow | (20.7M) | (27.3M) | (48.1M) | (52.4M) | (31.5M) | (33.1M) | |
| Depreciation | 436.4K | 619.0K | 870.3K | 994.8K | 1.0M | 760.8K | |
| Capital Expenditures | 1.2M | 864.7K | 2.4M | 1.3M | 48.7K | 46.3K | |
| Net Income | (20.5M) | (29.9M) | (50.9M) | (62.5M) | (32.3M) | (34.0M) | |
| End Period Cash Flow | 9.2M | 5.1M | 30.4M | 34.7M | 3.2M | 3.1M |
Neximmune Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Neximmune or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Neximmune's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Neximmune stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.71 | |
β | Beta against NYSE Composite | 1.13 | |
σ | Overall volatility | 13.90 | |
Ir | Information ratio | -0.05 |
Neximmune Volatility Alert
Neximmune is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Neximmune's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Neximmune's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Neximmune Fundamentals Vs Peers
Comparing Neximmune's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Neximmune's direct or indirect competition across all of the common fundamentals between Neximmune and the related equities. This way, we can detect undervalued stocks with similar characteristics as Neximmune or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Neximmune's fundamental indicators could also be used in its relative valuation, which is a method of valuing Neximmune by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Neximmune to competition |
| Fundamentals | Neximmune | Peer Average |
| Return On Equity | -1.81 | -0.31 |
| Return On Asset | -0.71 | -0.14 |
| Current Valuation | 1.65 M | 16.62 B |
| Shares Outstanding | 1.37 M | 571.82 M |
| Shares Owned By Insiders | 20.71 % | 10.09 % |
| Shares Owned By Institutions | 8.04 % | 39.21 % |
| Number Of Shares Shorted | 17.82 K | 4.71 M |
| Price To Book | 0.57 X | 9.51 X |
| EBITDA | (28.17 M) | 3.9 B |
| Net Income | (32.34 M) | 570.98 M |
| Cash And Equivalents | 53.13 M | 2.7 B |
| Cash Per Share | 2.20 X | 5.01 X |
| Total Debt | 68.81 K | 5.32 B |
| Debt To Equity | 0.02 % | 48.70 % |
| Current Ratio | 6.54 X | 2.16 X |
| Book Value Per Share | 3.29 X | 1.93 K |
| Cash Flow From Operations | (31.43 M) | 971.22 M |
| Short Ratio | 0.19 X | 4.00 X |
| Earnings Per Share | (30.82) X | 3.12 X |
| Target Price | 2.0 | |
| Number Of Employees | 6 | 18.84 K |
| Beta | 1.88 | -0.15 |
| Market Capitalization | 4.78 M | 19.03 B |
| Total Asset | 8.59 M | 29.47 B |
| Retained Earnings | (222.59 M) | 9.33 B |
| Working Capital | 316.73 K | 1.48 B |
| Net Asset | 8.59 M |
Note: Conversion by Roemer Alan S of 12268 shares of Neximmune [view details]
Neximmune Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Neximmune . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 5670.77 | |||
| Daily Balance Of Power | 0.3265 | |||
| Rate Of Daily Change | 1.05 | |||
| Day Median Price | 3.65 | |||
| Day Typical Price | 3.65 | |||
| Price Action Indicator | 0.085 | |||
| Period Momentum Indicator | 0.16 |
About Neximmune Buy or Sell Advice
When is the right time to buy or sell Neximmune? Buying financial instruments such as Neximmune Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 6.2M | 7.4M | 3.7B | 3.9B | Total Assets | 91.0M | 43.1M | 8.6M | 8.2M |
Use Investing Ideas to Build Portfolios
In addition to having Neximmune in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run High Yield ETFs Thematic Idea Now
High Yield ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The High Yield ETFs theme has 95 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize High Yield ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Neximmune Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Neximmune Stock please use our How to Invest in Neximmune guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Neximmune Stock analysis
When running Neximmune's price analysis, check to measure Neximmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neximmune is operating at the current time. Most of Neximmune's value examination focuses on studying past and present price action to predict the probability of Neximmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neximmune's price. Additionally, you may evaluate how the addition of Neximmune to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |
Is Neximmune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neximmune. If investors know Neximmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neximmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (30.82) | Return On Assets (0.71) | Return On Equity (1.81) |
The market value of Neximmune is measured differently than its book value, which is the value of Neximmune that is recorded on the company's balance sheet. Investors also form their own opinion of Neximmune's value that differs from its market value or its book value, called intrinsic value, which is Neximmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neximmune's market value can be influenced by many factors that don't directly affect Neximmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neximmune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neximmune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neximmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.